Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
121.40
-2.62 (-2.11%)
Nov 20, 2026, 4:00 PM EST - Market closed
Protagonist Therapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $190 | Buy | Maintains | $190 | +56.51% | Nov 10, 2026 |
| UBS | UBS | Buy Maintains $184 | Buy | Maintains | $184 | +51.57% | Nov 10, 2026 |
| Wedbush | Wedbush | Buy Maintains $173 | Buy | Maintains | $173 | +42.50% | Nov 10, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $149 → $151 | Buy | Reiterates | $149 → $151 | +24.38% | Nov 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $170 → $221 | Buy | Reiterates | $170 → $221 | +82.04% | Nov 6, 2026 |
| Barclays | Barclays | Buy Maintains $180 | Buy | Maintains | $180 | +48.27% | Nov 6, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $155 → $160 | Buy | Reiterates | $155 → $160 | +31.80% | Oct 21, 2026 |
| Citi | Citi | Buy Maintains $182 | Buy | Maintains | $182 | +49.92% | Oct 15, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.